Safety and immunogenicity of 2010-2011 A/H1N1pdm09-containing trivalent inactivated influenza vaccine in adults previously given AS03-adjuvanted H1N1 2009 pandemic vaccine: Results of a randomized trial

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 1, 2013, Pages 136-143

  Scheifele, David W ^a   Dionne, Marc ^b   Ward, Brian J ^c   Cooper, Curtis ^d   Vanderkooi, Otto G ^e   Li, Yan ^f   Halperin, Scott A ^g  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Institut Nationale de Santé Publique du Québec   (Canada)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

^e UNIVERSITY OF CALGARY   (Canada)

^f PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^g DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Adjuvant; Adults; Immunization; Influenza; Pandemic; Vaccine safety

Indexed keywords

IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; INFLUENZA VACCINE; PLACEBO; TRIPLE VACCINE;

2009 H1N1 INFLUENZA; ADULT; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CHEST TIGHTNESS; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DIARRHEA; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHAGIA; DYSPNEA; EYE REDNESS; FACE EDEMA; FAINTNESS; FATIGUE; FEMALE; HEART PALPITATION; HEMAGGLUTINATION INHIBITION TEST; HOARSENESS; HUMAN; HYPERVENTILATION; IMMUNOGENICITY; INFLUENZA VACCINATION; INJECTION SITE PAIN; INJECTION SITE PARESTHESIA; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; NAUSEA; NONHUMAN; PREVENTIVE HEALTH SERVICE; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SLEEP DISORDER; SORE THROAT; VIRUS STRAIN; VOMITING; WHEEZING;

ADULT; ANTIBODIES, VIRAL; CANADA; CROSS-OVER STUDIES; DRUG TOXICITY; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MIDDLE AGED; PLACEBOS; VACCINES, INACTIVATED;

EID: 84874708582     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.22619     Document Type: Article

References (26)

1. Girard MP, Tam JS, Assossou OM, Kieny MP. The 2009 A (H1N1) influenza virus pandemic: A review. Vaccine 2010; 28:4895-902; PMID:20553769; http://dx.doi.org/10.1016/j.vaccine.2010.05.031.
2. Ferguson M, Risi G, Davis M, Sheldon E, Baron M, Li P, et al. Safety and long-term humoral immune response in adults after vaccination with an H1N1 2009 pandemic influenza vaccine with or without AS03 adjuvant. J Infect Dis 2012; 205:733-44; PMID:22315336; http://dx.doi.org/10.1093/infdis/jir641.
3. Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 2010; 28:1740-5; PMID:20034605; http://dx.doi.org/10.1016/j.vaccine.2009.12.014.
4. Scheifele DW, Ward BJ, Dionne M, Vanderkooi O, Loeb M, Coleman BL, et al. Compatibility of AS03-adjuvanted A/H1N1pdm09 and seasonal trivalent influenza vaccines in adults: results of a randomized, controlled trial. Vaccine, In press.
5. Rubinstein E, Predy G, Sauvé L, Hammond GW, Aoki F, Sikora C, et al. The responses of Aboriginal Canadians to adjuvanted pandemic (H1N1) 2009 influenza vaccine. CMAJ 2011; 183:E1033-7; PMID:21788422; http://dx.doi.org/10. 1503/cmaj.110196.
6. Canadian community health survey: H1N1 vaccinations. Ottawa (ON): Statistics Canada; 2010. Available: www.statcan.gc.ca/daily-quotidien/100719/ dq100719b-eng.htm (accessed 2011 Sept 12).
7. Beyer WEP, Nauta JJP, Palache AM, Giezeman KM, Osterhaus ADME. Immunogenicity and safety of inactivated influenza vaccines in primed populations: a systematic literature review and meta-analysis. Vaccine 2011; 29:5785-92; PMID:21624411; http://dx.doi.org/10.1016/j.vaccine.2011.05.040.
8. World Health Organization. Recommended viruses for influenza vaccines for use in the 2010-2011 northern hemisphere influenza season. Available: www.who.int/influenza/vaccines/recommendations/recommendation2010-11north/en/ index/html (accessed 2011 Sept 12).
9. Scheifele DW, Ochnio JJ, Halperin SA. Cellular immunity as a potential cause of local reactions to booster vaccination with diphtheria and tetanus toxoids and acellular pertussis antigens. Pediatr Infect Dis J 2009; 28:985-9; PMID:19755930; http://dx.doi.org/10.1097/INF.0b013e3181a9cc2a.
10. Rowe J, Yerkovich ST, Richmond P, Suriyaarachchi D, Fisher E, Feddema L, et al. Th2-associated local reactions to the acellular diphtheria-tetanus- pertussis vaccine in 4-to 6-year-old children. Infect Immun 2005; 73:8130-5; PMID:16299307; http://dx.doi.org/10.1128/IAI.73.12.8130-8135.2005.
11. Levine L, Edsall G. Tetanus toxoid: what determines reaction proneness? J Infect Dis 1981; 144:376; PMID:7288216; http://dx.doi.org/10.1093/infdis/144.4. 376.
12. Armstrong PK, Dowse GK, Effler PV, Carcione D, Blyth CC, Richmond PC, et al. Epidemiological study of severe febrile reactions in young children in Western Australia caused by a 2010 trivalent inactivated influenza vaccine. BMJ Open 2011; 1:e000016; PMID:22021725; http://dx.doi.org/10.1136/bmjopen-2010- 000016.
13. Scheifele DW, Marty K, LaJeunesse C, Fan SY, Bjornson G, Langley JM, et al. Strategies for successful rapid trials of influenza vaccine. Clin Trials 2011; 8:699-704; PMID:21900340; http://dx.doi.org/10.1177/1740774511419868.
14. Scheifele DW, Duval B, Russell ML, Warrington R, DeSerres G, Skowronski DM, et al. Ocular and respiratory symptoms attributable to inactivated split influenza vaccine: evidence from a controlled trial involving adults. Clin Infect Dis 2003; 36:850-7; PMID:12652385; http://dx.doi.org/10.1086/368189.
15. Jackson LA, Gaglani MJ, Keyserling HL, Balser J, Bouveret N, Fries L, et al. Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons. BMC Infect Dis 2010; 10:71; PMID:20236548; http://dx.doi.org/10.1186/ 1471-2334-10-71.
16. Walker WT, de Whalley P, Andrews N, Oeser C, Casey M, Michaelis L, et al. H1N1 antibody persistence 1 year after immunization with an adjuvanted or whole-virion pandemic vaccine and immunogenicity and reactogenicity of subsequent seasonal influenza vaccine: a multicenter follow-on study. Clin Infect Dis 2012; 54:661-9; PMID:22267719; http://dx.doi.org/10.1093/cid/cir905.
17. Gilca V, De Serres G, Hamelin ME, Boivin G, Ouakki M, Boulianne N, et al. Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children. Vaccine 2011; 30:35-41; PMID:22063386; http://dx.doi.org/10.1016/j. vaccine.2011.10.062.
18. Langley JM, Scheifele DW, Quach C, Vanderkooi O, Ward B, McNeil S, et al. Safety and immunogenicity of 2010-2011 H1N1 2009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N1 2009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study. Vaccine 2012; 23:3389-94; http://dx.doi.org/10.1016/j. vaccine.2012.03.046.
19. De Serres G, Grenier JL, Toth E, Ménard S, Roussel R, Tremblay M, et al. The clinical spectrum of the oculo-respiratory syndrome after influenza vaccination. Vaccine 2003; 21:2354-61; PMID:12744866; http://dx.doi.org/10.1016/ S0264-410X(03)00094-X.
20. Skowronski DM, Strauss B, De Serres G, MacDonald D, Marion SA, Naus M, et al. Oculo-respiratory syndrome: a new influenza vaccine-associated adverse event? Clin Infect Dis 2003; 36:705-13; PMID:12627354; http://dx.doi.org/10. 1086/367667.
21. De Serres G, Toth E, Ménard S, Grenier JL, Roussel R, Tremblay M, et al. Oculo-respiratory syndrome after influenza vaccination: trends over four influenza seasons. Vaccine 2005; 23:3726-32; PMID:15882534; http://dx.doi.org/ 10.1016/j.vaccine.2005.01.154.
22. Boulianne N, De Serres G, Duval B, Shadmani R, Rochette L. Clinical manifestations and incidence of oculo-respiratory syndrome following influenza vaccination-Quebec, 2000. Can Commun Dis Rep 2001; 27:85-90; PMID:11396047.
23. Sever JL, Brenner AI, Gale AD, Lyle JM, Moulton LH, West DJ; Anthrax Vaccine Export Committee. Safety of anthrax vaccine: a review by the Anthrax Vaccine Expert Committee (AVEC) of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS). Pharmacoepidemiol Drug Saf 2002; 11:189-202; PMID:12051118; http://dx.doi.org/10.1002/pds.712.
24. Huijskens E, Rossen J, Mulder P, van Beek R, van Vugt H, Verbakel J, et al. Immunogenicity, boostability, and sustainability of the immune response after vaccination against Influenza A virus (H1N1) 2009 in a healthy population. Clin Vaccine Immunol 2011; 18:1401-5; PMID:21795459; http://dx.doi.org/10.1128/ CVI.05046-11.
25. World Health Organization. WHO Manual on Animal Influenza Diagnosis and Surveillance, 2002. Available at: www.who.int/vaccine research/diseases/ influenza/WHO manual on animal-diagnosis and surveillance 2002 5.pdf [accessed February 15, 2012]
26. Wood JM, Newman RW, Ploss K. The use of correlates of immunity in European Union licensing of influenza vaccines. Dev Biol (Basel) 2003; 115:9-16; PMID:15088770.